Literature DB >> 20007519

A peripheral neuroimmune link: glutamate agonists upregulate NMDA NR1 receptor mRNA and protein, vimentin, TNF-alpha, and RANTES in cultured human synoviocytes.

Terry A McNearney1, Yinghong Ma, Yueping Chen, Giulio Taglialatela, Huaizhi Yin, Wen-Ru Zhang, Karin N Westlund.   

Abstract

Human primary and clonal synovial cells were incubated with glutamate receptor agonists to assess their modulating influence on glutamate receptors N-methyl-d-aspartate (NMDA) NR1 and NR2 and inflammatory cytokines to determine potential for paracrine or autocrine (neurocrine) upregulation of glutamate receptors, as has been shown for bone and chondrocytes. Clonal SW982 synoviocytes constitutively express vimentin, smooth muscle actin (SMA), and NMDA NR1 and NR2. Coincubation (6 h) with glutamate agonists NMDA (5 microM), and the NMDA NR1 glycine site activator (+/-)1-aminocyclopentane-cis-1,3-dicarboxylic acid (5 muM), significantly increases cellular mRNA and protein levels of glutamate receptors, as well as increasing vimentin, SMA, tumor necrosis factor-alpha, and RANTES (regulated on activation, normal T-cell expressed and secreted), assessed qualitatively and quantitatively with nucleotide amplification, image analysis of immunocytochemical staining, fluorescein-activated cell sorting, Western blotting, and immunoassays. Human primary synovial cells harvested from patients with arthritic conditions also constitutively expressed NMDA NR1 with increases after agonist treatment. Glutamate receptor agonist-induced increases were blocked by the noncompetitive glutamate antagonist MK-801 (8 microg/ml) and NR1 blocking antibody. Coincubation with glutamate agonists and phorbol 12-myristate 13-acetate, a protein kinase C activator, significantly enhanced mean levels of TNF-alpha and RANTES in SW982 cell supernatants compared with incubation with either agent alone. Increases were diminished with protein kinase inhibitor and NR1 blocking antibody. The functional activation of glutamate receptors on human synoviocytes establishes a neurogenic cell signaling link between neurotransmitter glutamate released from nerve terminals and target cells in the joint capsule. The influence of glutamate on subsequent release of cellular proinflammatory mediators in non-neural tissue for activation of downstream immune events supports a peripheral neuroimmune link in arthritis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20007519      PMCID: PMC2838657          DOI: 10.1152/ajpregu.00452.2009

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  60 in total

1.  c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis.

Authors:  Z Han; D L Boyle; L Chang; B Bennett; M Karin; L Yang; A M Manning; G S Firestein
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

2.  Group I metabotropic glutamate receptor antagonists block secondary thermal hyperalgesia in rats with knee joint inflammation.

Authors:  Liping Zhang; Ying Lu; Ying Chen; Karin N Westlund
Journal:  J Pharmacol Exp Ther       Date:  2002-01       Impact factor: 4.030

3.  Antidromic vasodilatation and neurogenic inflammation.

Authors:  J Szolcsányi
Journal:  Agents Actions       Date:  1988-02

Review 4.  Identification of novel signaling pathways during functional adaptation of the skeleton to mechanical loading: the role of glutamate as a paracrine signaling agent in the skeleton.

Authors:  T M Skerry
Journal:  J Bone Miner Metab       Date:  1999       Impact factor: 2.626

5.  The NMDA type glutamate receptors expressed by primary rat osteoblasts have the same electrophysiological characteristics as neuronal receptors.

Authors:  Y Gu; P G Genever; T M Skerry; S J Publicover
Journal:  Calcif Tissue Int       Date:  2002-02-19       Impact factor: 4.333

Review 6.  Rheumatoid arthritis: regulation of synovial inflammation.

Authors:  Susan E Sweeney; Gary S Firestein
Journal:  Int J Biochem Cell Biol       Date:  2004-03       Impact factor: 5.085

7.  Effect of glutamate receptor antagonists and antirheumatic drugs on proliferation of synoviocytes in vitro.

Authors:  Jolanta Parada-Turska; Wojciech Rzeski; Maria Majdan; Martyna Kandefer-Szerszeń; Waldemar A Turski
Journal:  Eur J Pharmacol       Date:  2006-03-13       Impact factor: 4.432

8.  Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis.

Authors:  Deepa R Hammaker; David L Boyle; Martine Chabaud-Riou; Gary S Firestein
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

9.  Fiber types contributing to dorsal root reflexes induced by joint inflammation in cats and monkeys.

Authors:  K A Sluka; H Rees; K N Westlund; W D Willis
Journal:  J Neurophysiol       Date:  1995-09       Impact factor: 2.714

10.  Protective effect of sensory denervation in inflammatory arthritis (evidence of regulatory neuroimmune pathways in the arthritic joint).

Authors:  D Kane; J C Lockhart; P V Balint; C Mann; W R Ferrell; I B McInnes
Journal:  Ann Rheum Dis       Date:  2004-05-21       Impact factor: 19.103

View more
  15 in total

Review 1.  Glutamate pharmacology and metabolism in peripheral primary afferents: physiological and pathophysiological mechanisms.

Authors:  Kenneth E Miller; E Matthew Hoffman; Mathura Sutharshan; Ruben Schechter
Journal:  Pharmacol Ther       Date:  2011-01-26       Impact factor: 12.310

2.  Potential role of fibroblast-like synoviocytes in joint damage induced by Brucella abortus infection through production and induction of matrix metalloproteinases.

Authors:  Romina Scian; Paula Barrionuevo; Guillermo H Giambartolomei; Emilio A De Simone; Silvia I Vanzulli; Carlos A Fossati; Pablo C Baldi; M Victoria Delpino
Journal:  Infect Immun       Date:  2011-07-05       Impact factor: 3.441

3.  Excitatory amino acids display compartmental disparity between plasma and synovial fluid in clinical arthropathies.

Authors:  Terry A McNearney; Karin N Westlund
Journal:  Int J Clin Exp Pathol       Date:  2013-02-15

4.  Different inhibitory effects of kynurenic acid and a novel kynurenic acid analogue on tumour necrosis factor-α (TNF-α) production by mononuclear cells, HMGB1 production by monocytes and HNP1-3 secretion by neutrophils.

Authors:  Zoltán Tiszlavicz; Balázs Németh; Ferenc Fülöp; László Vécsei; Katalin Tápai; Imre Ocsovszky; Yvette Mándi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-02-19       Impact factor: 3.000

5.  Impact of central and peripheral TRPV1 and ROS levels on proinflammatory mediators and nociceptive behavior.

Authors:  Karin N Westlund; Mikhail Y Kochukov; Ying Lu; Terry A McNearney
Journal:  Mol Pain       Date:  2010-08-06       Impact factor: 3.395

Review 6.  Ketamine and peripheral inflammation.

Authors:  Marc De Kock; Sebastien Loix; Patricia Lavand'homme
Journal:  CNS Neurosci Ther       Date:  2013-04-10       Impact factor: 5.243

7.  AMPA/kainate glutamate receptor antagonists prevent posttraumatic osteoarthritis.

Authors:  Cleo S Bonnet; Sophie J Gilbert; Emma J Blain; Anwen S Williams; Deborah J Mason
Journal:  JCI Insight       Date:  2020-07-09

8.  Expression of tumor necrosis factor-α and interleukin-1β genes in the cochlea and inferior colliculus in salicylate-induced tinnitus.

Authors:  Juen-Haur Hwang; Jin-Cherng Chen; Shan-Ying Yang; Ming-Fu Wang; Yin-Ching Chan
Journal:  J Neuroinflammation       Date:  2011-04-09       Impact factor: 8.322

9.  Agmatine protects Müller cells from high-concentration glucose-induced cell damage via N-methyl-D-aspartic acid receptor inhibition.

Authors:  Ning Han; Li Yu; Zhidu Song; Lifu Luo; Yazhen Wu
Journal:  Mol Med Rep       Date:  2015-03-24       Impact factor: 2.952

Review 10.  Coupled cell networks are target cells of inflammation, which can spread between different body organs and develop into systemic chronic inflammation.

Authors:  Elisabeth Hansson; Eva Skiöldebrand
Journal:  J Inflamm (Lond)       Date:  2015-07-25       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.